Members of the ACCC IO Institute Executive Committee discuss the potential benefits big data could play in helping providers determine who should be tested for immunotherapy and why It’s essential for community practices to understand how to use biomarkers to stratify patients and select appropriate patients for IO clinical trials. (features Lee Schwartzberg, MD, FACP; Jennie Crews, MD, MMM, FACP; and Ivo Abraham PhD, RN)
Ran Ranshef, MD, MSc, spoke to the ACCC Immuno-Oncology Institute about advancements in chimeric antigen receptor (CAR) T-cell therapy presented at the 2018 American Society of Hematology (ASH) Annual Meeting.
In the current oncology clinical trials landscape, many barriers
remain to clinical trial enrollment that affect both the oncologist
and the patient. Among these are trial locations, strict eligibility
requirements, insufficient resources to support appropriate clinical
trial education and screening, as well as patient and provider
attitudes about trials.